| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
10 analysts have expressed a variety of opinions on Moderna (NASDAQ:MRNA) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 2 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $147.3, a high estimate of $214.00, and a low estimate of $106.00. This current average has increased by 4.01% from the previous average price target of $141.62.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Moderna. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Edward Tenthoff | Piper Sandler | Maintains | Overweight | $214.00 | $214.00 |
| Cory Kasimov | Evercore ISI Group | Maintains | In-Line | $120.00 | $120.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $179.00 | $163.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $160.00 | $135.00 |
| Cory Kasimov | Evercore ISI Group | Announces | In-Line | $120.00 | - |
| Eliana Merle | UBS | Raises | Buy | $151.00 | $143.00 |
| Bill Maughan | Canaccord Genuity | Raises | Hold | $106.00 | $91.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $135.00 | $125.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $163.00 | $142.00 |
| Michael Yee | Jefferies | Maintains | Buy | $125.00 | - |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Moderna's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Moderna analyst ratings.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Moderna's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -90.91%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Moderna's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -703.59%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Moderna's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -8.81%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Moderna's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Moderna's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MRNA
